Exhalation Delivery System With Fluticasone Effective for Rhinosinusitis

2024-01-26

临床结果

FRIDAY, Jan. 26, 2024 -- For patients with chronic rhinosinusitis (CRS), an exhalation delivery system that delivers fluticasone (EDS-FLU) to sinonasal areas above the inferior turbinate is efficacious, irrespective of nasal polyps, according to a study published online Jan. 18 in the Journal of Allergy and Clinical Immunology: In Practice.

James N. Palmer, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined EDS-FLU efficacy for CRS in two randomized, EDS-placebo-controlled trials in adults with CRS irrespective of polyps (ReOpen1; 332 patients) or exclusively without polyps (ReOpen2; 223 patients). For 24 weeks, patients received EDS-FLU one or two sprays/nostril or EDS-placebo twice daily.

The researchers found that the composite symptom score least-squares mean change for EDS-FLU one or two sprays/nostril versus EDS-placebo was −1.58 and −1.60 versus −0.62 in ReOpen1, and −1.54 and −1.74 versus −0.81 in ReOpen2. Sinus opacification least-squares mean change for one or two sprays/nostril of EDS-FLU versus EDS-placebo was −5.58 and −6.20 versus −1.60 in ReOpen1 and −7.00 and −5.14 versus +1.19 in ReOpen2. Compared with EDS-placebo, acute disease exacerbations were reduced by 56 to 66 percent with EDS-FLU. For patients using standard-delivery nasal steroid products just before entering the study, there were significant symptom reductions of a similar magnitude observed. Similar adverse events were seen to those with standard-delivery intranasal steroids.

"These findings provide strong evidence for an effective, noninvasive treatment option for people who continue to experience symptoms after over-the-counter medications have failed," Palmer said in a statement.

Several authors disclosed ties to pharmaceutical companies, including OptiNose US, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Posted January 2024

More news resources

FDA Medwatch Drug Alerts

Daily MedNews

News for Health Professionals

New Drug Approvals

New Drug Applications

Drug Shortages

Clinical Trial Results

Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.